Abstract
Amyotrophic lateral sclerosis consists of multiple diseases that lead to a common endpoint that initiates motor neuron loss. The difficulty in developing treatments is that both the presentation and the course of the disease differs for patients and there aren’t methods to stratify patients in clinical trials that are expected to benefit from a drug, thus most treatments that were positive in animal studies fail in Phase 2 human studies. It is possible harnessing innate immune responses involved with the cell danger responses may be a starting point to stack therapies in patients. A major step in regulating the cell danger response is creating a retro-inverso thymopentin that can increase innate immune targets to regulate T cell responses.
Recent work on thymopentin bring a major contribution to the ALS field and we present FC-12738 designed to regulate the cell danger response by natural innate immune pathways.